Suppr超能文献

[原发性肺肉瘤]

[Primary pulmonary sarcomas].

作者信息

Jakubcová T, Jakubec P

机构信息

Klinika plicních nemocí a tuberkulózy FN a LF UP, Olomouc.

出版信息

Klin Onkol. 2009;22(4):139-53.

Abstract

Primary pulmonary sarcomas are rare diseases unlike lung carcinomas. The occurence of these sarcomas is between 0.013-0.40% of all malignant lung tumours. There are malignant mesenchymal tumours. They are flowing from the soft tissue of lung. The pulmonary sarcomas are heterogenic group with various biological behaviour. Their morfologic structure does not digger from the sarcomas of soft tissue. The primary pulmonary sarcomas occur more often in childhood and in young people unlike lung carcinomas. Radiation and some toxic substances are noted risk factors. Some gene mutations, infectious pathoghens and contraception have a possible impact on the origin of some types of the sarcomas. The current hypothesis is, that most of the sarcomas, if not all sarcomas, stem from primitive multipotent mesenchymal cell by malignant transformation in one or more lines. The diagnostic standard is biopsy from tumour with histologic and immunohistochemistry examination of a sample. The basic diagnostic problem is exclusion of a secondary origin of sarcomatic cells in the lung, because pulmonary metastasis of extrapulmonary sarcomas are more often than the primary pulmonary involvement.The optimal treatment is a resection of the tumour.The other therapeutic modalities are radiotherapy and chemotherapy, but results of these modalities are unsatisfactory. There are various chemotherapeutic regimes, monotherapy or combination regimes. The basic cytostatics are doxorubicine, iphosphamide, dacarbazine. Problems of the chemotherapy are high toxicity and relatively low curative effect about 20%.The first studies with biological treatment of the sarcomas of soft tissue have been published recently.This types of drugs could be a part of the complex management of these primary pulmonary tumours in the future. The primary pulmonary sarcomas have mostly aggresive course and often recur. Their prognosis is usually not very good. The survival median is 48 months and 5-years survival ranges between 38 and 48%. Prognostic factors are the size of tumour, histological type, grading, clinical stage and measure of a surgery major.

摘要

原发性肺肉瘤是不同于肺癌的罕见疾病。这些肉瘤的发生率占所有恶性肺肿瘤的0.013 - 0.40%。它们是恶性间充质肿瘤,起源于肺的软组织。肺肉瘤是具有多种生物学行为的异质性群体,其形态结构与软组织肉瘤并无差异。与肺癌不同,原发性肺肉瘤更常发生于儿童和年轻人。辐射和一些有毒物质是已知的危险因素。一些基因突变、感染性病原体和避孕措施可能对某些类型肉瘤的起源有影响。目前的假说认为,大多数肉瘤,如果不是所有肉瘤的话,是由原始多能间充质细胞通过一条或多条途径的恶性转化产生的。诊断标准是对肿瘤进行活检,并对样本进行组织学和免疫组化检查。基本的诊断问题是排除肺内肉瘤细胞的继发性起源,因为肺外肉瘤的肺转移比原发性肺受累更为常见。最佳治疗方法是切除肿瘤。其他治疗方式包括放疗和化疗,但这些方式的效果并不理想。有多种化疗方案,包括单药治疗或联合治疗方案。基本的细胞毒性药物有多柔比星、异环磷酰胺、达卡巴嗪。化疗的问题是毒性高且疗效相对较低,约为20%。最近已发表了关于软组织肉瘤生物治疗的首批研究。这类药物未来可能成为这些原发性肺肿瘤综合治疗的一部分。原发性肺肉瘤大多病程侵袭性强且常复发,其预后通常不太好。中位生存期为48个月,5年生存率在38%至48%之间。预后因素包括肿瘤大小、组织学类型、分级、临床分期和手术切除范围。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验